AstraZeneca (AZNCF) Institutional Ownership $141.12 +2.88 (+2.08%) As of 01:14 PM Eastern Add Compare Share Share Ownership Stock AnalysisChartDividendFinancialsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock Institutional Ownership Changes (13F Filings) for AstraZeneca (OTCMKTS:AZNCF)CurrentInstitutional OwnershipPercentage40.87%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$154.61KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$16.26M Get AZNCF Insider Trade Alerts Want to know when executives and insiders are buying or selling AstraZeneca stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data AZNCF Institutional Buying and Selling by Quarter AstraZeneca Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/3/2025 Boston Common Asset Management LLC185,930$27.01M0.8%-14.2%0.000% 1/15/2025 Boston Common Asset Management LLC216,775$28.26M0.8%-17.3%0.000% 10/22/2024 Eagle Bay Advisors LLC1,001$156K0.1%N/A0.000% 10/9/2024 Boston Common Asset Management LLC262,273$40.77M1.1%-9.2%0.000% 7/8/2024 Boston Common Asset Management LLC288,790$45.11M1.2%-3.6%0.000% 5/16/2024 Kennedy Capital Management LLC37,554$5.07M0.1%N/A0.000% 1/9/2024 Boston Common Asset Management LLC301,010$40.58M0.9%-2.8%0.000% 10/11/2023 Boston Common Asset Management LLC309,762$41.97M1.0%-1.1%0.000% 7/24/2023 Boston Common Asset Management LLC313,065$44.88M1.0%+15.5%0.000% 5/17/2023 Boston Common Asset Management LLC271,130$37.65M0.8%N/A0.000% 5/1/2023Vigilant Capital Management LLC647$90K0.0%-16.2%0.000% (Data available from 1/1/2016 forward) AZNCF Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of AZNCF shares? During the previous two years, the following institutional investors and hedge funds held shares of AstraZeneca shares: Boston Common Asset Management LLC ($27.01M), and Kennedy Capital Management LLC ($5.07M), Eagle Bay Advisors LLC ($156K).Learn more on AZNCF's institutional investors. What percentage of AstraZeneca stock is owned by institutional investors? 40.87% of AstraZeneca stock is owned by institutional investors. Learn more on AZNCF's institutional investor holdings. Which institutional investors have been buying AstraZeneca stock? The following institutional investors have purchased AstraZeneca stock in the last 24 months: Boston Common Asset Management LLC ($41.94K), Kennedy Capital Management LLC ($37.55K), and Eagle Bay Advisors LLC ($1.00K). How much institutional buying is happening at AstraZeneca? Institutional investors have bought a total of 80,490 shares in the last 24 months. This purchase volume represents approximately $11.33M in transactions. Which AstraZeneca major shareholders have been selling company stock? The following institutional investors have sold AstraZeneca stock in the last 24 months: Boston Common Asset Management LLC ($125.81K). How much institutional selling is happening at AstraZeneca? Institutional investors have sold a total of 125,808 shares in the last 24 months. This volume of shares sold represents approximately $17.88M in transactions. This page (OTCMKTS:AZNCF) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.